{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T13:12:29Z","timestamp":1788441149507,"version":"build-2803163510"},"reference-count":146,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.phrs.2021.105695","type":"journal-article","created":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T23:42:54Z","timestamp":1622504574000},"page":"105695","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"special_numbering":"C","title":["Histone deacetylase 2 selective inhibitors: A versatile therapeutic strategy as next generation drug target in cancer therapy"],"prefix":"10.1016","volume":"170","author":[{"given":"Manasa Gangadhar","family":"Shetty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9608-5939","authenticated-orcid":false,"given":"Padmini","family":"Pai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renita Esther","family":"Deaver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kapaettu","family":"Satyamoorthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kampa Sundara","family":"Babitha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2021.105695_bib1","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S0969-2126(01)00690-6","article-title":"Structure of histone deacetylases: insights into substrate recognition and catalysis","volume":"9","author":"Marmorstein","year":"2001","journal-title":"Structure"},{"key":"10.1016\/j.phrs.2021.105695_bib2","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0092-8674(00)80211-1","article-title":"What\u2019s up and down with histone deacetylation and transcription?","volume":"89","author":"Pazin","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2021.105695_bib3","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S1535-6108(04)00114-X","article-title":"Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis","volume":"5","author":"Zhu","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.phrs.2021.105695_bib4","first-page":"8331","article-title":"Heterogeneous transforming growth factor (TGF)-\u03b2 unresponsiveness and loss of TGF-\u03b2 receptor type II expression caused by histone deacetylation in lung cancer cell lines","volume":"61","author":"Osada","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2021.105695_bib5","doi-asserted-by":"crossref","first-page":"12447","DOI":"10.1111\/cpr.12447","article-title":"Pharmacological or transcriptional inhibition of both HDAC1 and 2 leads to cell cycle blockage and apoptosis via p21 Waf1\/Cip1 and p19 INK4d upregulation in hepatocellular carcinoma","volume":"51","author":"Zhou","year":"2018","journal-title":"Cell Prolif."},{"key":"10.1016\/j.phrs.2021.105695_bib6","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/35042612","article-title":"Deacetylation of p53 modulates its effect on cell growth and apoptosis","volume":"408","author":"Luo","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2021.105695_bib7","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/386761a0","article-title":"Gatekeepers and caretakers","volume":"386","author":"Kinzler","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2021.105695_bib8","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nrc1799","article-title":"Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction?","volume":"6","author":"Baylin","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2021.105695_bib9","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/143269","article-title":"Targeting HDACs: a promising therapy for Alzheimer\u2019s disease","volume":"2011","author":"Xu","year":"2011","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.phrs.2021.105695_bib10","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1021\/acschemneuro.6b00372","article-title":"Expression of HDAC2 but not HDAC1 transcript is reduced in dorsolateral prefrontal cortex of patients with schizophrenia","volume":"8","author":"Schroeder","year":"2017","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.phrs.2021.105695_bib11","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.neurobiolaging.2018.02.018","article-title":"Upregulation of histone deacetylase 2 in laser capture nigral microglia in Parkinson\u2019s disease","volume":"68","author":"Tan","year":"2018","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.phrs.2021.105695_bib12","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1161\/01.RES.0000338570.27156.84","article-title":"Activation of histone deacetylase 2 by inducible heat shock protein 70 in cardiac hypertrophy","volume":"103","author":"Kee","year":"2008","journal-title":"Circ. Res."},{"key":"10.1016\/j.phrs.2021.105695_bib13","doi-asserted-by":"crossref","first-page":"131","DOI":"10.5483\/BMBRep.2015.48.3.242","article-title":"Role of histone deacetylase 2 and its posttranslational modifications in cardiac hypertrophy","volume":"48","author":"Eom","year":"2015","journal-title":"BMB Rep."},{"key":"10.1016\/j.phrs.2021.105695_bib14","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/nm1552","article-title":"Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3\u03b2 activity","volume":"13","author":"Trivedi","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2021.105695_bib15","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1161\/CIRCULATIONAHA.110.003665","article-title":"Casein kinase-2\u03b11 induces hypertrophic response by phosphorylation of histone deacetylase 2 S394 and its activation in the heart","volume":"123","author":"Eom","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2021.105695_bib16","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.devcel.2010.08.012","article-title":"Hopx and Hdac2 interact to modulate Gata4 acetylation and embryonic cardiac myocyte proliferation","volume":"19","author":"Trivedi","year":"2010","journal-title":"Dev. Cell"},{"key":"10.1016\/j.phrs.2021.105695_bib17","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrd2133","article-title":"Anticancer activities of histone deacetylase inhibitors","volume":"5","author":"Bolden","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2021.105695_bib18","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a026831","article-title":"HDACs and HDAC inhibitors in cancer development and therapy","volume":"6","author":"Li","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.phrs.2021.105695_bib19","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.3390\/nu6104273","article-title":"The role of dietary histone deacetylases (HDACs) inhibitors in health and disease","volume":"6","author":"Bassett","year":"2014","journal-title":"Nutrients"},{"key":"10.1016\/j.phrs.2021.105695_bib20","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0092-8674(78)90305-7","article-title":"Sodium butyrate inhibits histone deacetylation in cultured cells","volume":"14","author":"Candido","year":"1978","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2021.105695_bib21","first-page":"3688","article-title":"Effects of trichostatins on differentiation of murine erythroleukemia cells","volume":"47","author":"Yoshida","year":"1987","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2021.105695_bib22","doi-asserted-by":"crossref","first-page":"22429","DOI":"10.1016\/S0021-9258(18)41547-5","article-title":"Trapoxin, an antitumor cyclic tetrapeptide,is an irreversible inhibitor of mammalian histone deacetylase","volume":"268","author":"Kijima","year":"1993","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2021.105695_bib23","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/sj.bjc.6603851","article-title":"Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial","volume":"97","author":"Atmaca","year":"2007","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.phrs.2021.105695_bib24","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1600-0609.2008.01102.x","article-title":"A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia","volume":"81","author":"Gimsing","year":"2008","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.phrs.2021.105695_bib25","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/1078-0432.CCR-07-4262","article-title":"Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma","volume":"14","author":"Ellis","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2021.105695_bib26","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1158\/1078-0432.CCR-06-0511","article-title":"A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies","volume":"12","author":"Giles","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2021.105695_bib27","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1080\/10428190701817258","article-title":"Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma","volume":"49","author":"Richardson","year":"2008","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.phrs.2021.105695_bib28","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1158\/1078-0432.CCR-07-1461","article-title":"A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas","volume":"14","author":"Gore","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2021.105695_bib29","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.neuron.2008.10.015","article-title":"Deregulation of HDAC1 by p25\/Cdk5 in neurotoxicity","volume":"60","author":"Kim","year":"2008","journal-title":"Neuron"},{"key":"10.1016\/j.phrs.2021.105695_bib30","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1523\/JNEUROSCI.3344-05.2006","article-title":"Differential contributions of Caenorhabditis elegans histone deacetylases to Huntingtin polyglutamine toxicity","volume":"26","author":"Bates","year":"2006","journal-title":"J. Neurosci."},{"key":"10.1016\/j.phrs.2021.105695_bib31","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.bbcan.2014.07.010","article-title":"Histone deacetylase 2 controls p53 and is a critical factor in tumorigenesis","volume":"1846","author":"Wagner","year":"2014","journal-title":"Biochim. Biophys. Acta (BBA) Rev. Cancer"},{"key":"10.1016\/j.phrs.2021.105695_bib32","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jmb.2004.02.006","article-title":"Molecular evolution of the histone deacetylase family: Functional implications of phylogenetic analysis","volume":"338","author":"Gregoretti","year":"2004","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.phrs.2021.105695_bib33","unstructured":"https:\/\/www.uniprot.org\/uniprot\/Q13547, UniProt entry: Q13547. (Accessed 06 February 2021)."},{"key":"10.1016\/j.phrs.2021.105695_bib34","unstructured":"https:\/\/www.uniprot.org\/uniprot\/Q92769, UniProt entry: Q92769. (Accessed 06 February 2021)."},{"key":"10.1016\/j.phrs.2021.105695_bib35","unstructured":"https:\/\/www.uniprot.org\/uniprot\/O15379, UniProt entry: O15379. (Accessed 06 February 2021)."},{"key":"10.1016\/j.phrs.2021.105695_bib36","unstructured":"https:\/\/www.uniprot.org\/uniprot\/Q9BY41, UniProt entry: Q9BY41. (Accessed 06 February 2021)."},{"key":"10.1016\/j.phrs.2021.105695_bib37","unstructured":"https:\/\/www.uniprot.org\/uniprot\/P56524, Uni Prot entry: P56524. (Accessed 06 February 2021)."},{"key":"10.1016\/j.phrs.2021.105695_bib38","unstructured":"https:\/\/www.uniprot.org\/uniprot\/Q9UQL6, Uni Prot entry: P56524. (Accessed 06 February 2021)."},{"key":"10.1016\/j.phrs.2021.105695_bib39","unstructured":"https:\/\/www.uniprot.org\/uniprot\/Q8WUI4, Uni Prot entry: Q8WUI4. (Accessed 06 February 2021)."},{"key":"10.1016\/j.phrs.2021.105695_bib40","unstructured":"https:\/\/www.uniprot.org\/uniprot\/Q9UKV0, Uni Prot entry: Q9UKV0. (Accessed 06 February 2021)."},{"key":"10.1016\/j.phrs.2021.105695_bib41","unstructured":"https:\/\/www.uniprot.org\/uniprot\/Q9UBN7, Uni Prot entry: Q9UBN7. (Accessed 06 February 2021)."},{"key":"10.1016\/j.phrs.2021.105695_bib42","unstructured":"https:\/\/www.uniprot.org\/uniprot\/Q969S8, Uni Prot entry: Q969S8. (Accessed 06 February 2021)."},{"key":"10.1016\/j.phrs.2021.105695_bib43","unstructured":"https:\/\/www.uniprot.org\/uniprot\/Q96DB2, Uni Prot entry: Q96DB2. (Accessed 06 February 2021)."},{"key":"10.1016\/j.phrs.2021.105695_bib44","unstructured":"https:\/\/www.uniprot.org\/uniprot\/Q96EB6, Uni Prot entry: Q96EB6. (Accessed 06 February 2021)."},{"key":"10.1016\/j.phrs.2021.105695_bib45","unstructured":"https:\/\/www.uniprot.org\/uniprot\/Q8IXJ6, Uni Prot entry: Q8IXJ6. (Accessed 06 February 2021)."},{"key":"10.1016\/j.phrs.2021.105695_bib46","unstructured":"https:\/\/www.uniprot.org\/uniprot\/Q9NTG7, Uni Prot entry: Q9NTG7. (Accessed 06 February 2021)."},{"key":"10.1016\/j.phrs.2021.105695_bib47","unstructured":"https:\/\/www.uniprot.org\/uniprot\/Q9Y6E7, Uni Prot entry: Q9Y6E7. Accessed 06 February 2021)."},{"key":"10.1016\/j.phrs.2021.105695_bib48","unstructured":"https:\/\/www.uniprot.org\/uniprot\/Q9NXA8, Uni Prot entry: Q9NXA8. Accessed 06 February 2021)."},{"key":"10.1016\/j.phrs.2021.105695_bib49","unstructured":"https:\/\/www.uniprot.org\/uniprot\/Q8N6T7, Uni Prot entry: Q8N6T7. (Accessed 06 February 2021)."},{"key":"10.1016\/j.phrs.2021.105695_bib50","unstructured":"https:\/\/www.uniprot.org\/uniprot\/Q9NRC8, Uni Prot entry: Q9NRC8. (Accessed 06 February 2021)."},{"key":"10.1016\/j.phrs.2021.105695_bib51","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/nrm2346","article-title":"The Rpd3\/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men","volume":"9","author":"Yang","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.phrs.2021.105695_bib52","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1006\/geno.1998.5435","article-title":"Human histone deacetylase 2, HDAC2 (Human RPD3), is localized to 6q21 by radiation hybrid mapping","volume":"52","author":"Betz","year":"1998","journal-title":"Genomics"},{"key":"10.1016\/j.phrs.2021.105695_bib53","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.tips.2009.09.007","article-title":"HDAC2: a critical factor in health and disease","volume":"30","author":"Kr\u00e4mer","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.phrs.2021.105695_bib54","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1016\/j.bmcl.2010.03.091","article-title":"Exploration of the HDAC2 foot pocket: synthesis and SAR of substituted N-(2-aminophenyl) benzamides","volume":"20","author":"Bressi","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.phrs.2021.105695_bib55","unstructured":"https:\/\/www.rcsb.org\/structure\/3max, PDB ID: 3MAX, 060221. (Accessed 06 February 2021)."},{"key":"10.1016\/j.phrs.2021.105695_bib56","unstructured":"https:\/\/www.rcsb.org\/structure\/4LXZ, PDB ID: 4LXZ. (Accessed 06 February 2021)."},{"key":"10.1016\/j.phrs.2021.105695_bib57","unstructured":"https:\/\/www.rcsb.org\/structure\/4LY1, PDB ID: 4LY1. (Accessed 06 February 2021)."},{"key":"10.1016\/j.phrs.2021.105695_bib58","unstructured":"https:\/\/www.rcsb.org\/structure\/5IWG, PDB ID: 5IWG. (Accessed 06 February 2021)."},{"key":"10.1016\/j.phrs.2021.105695_bib59","unstructured":"https:\/\/www.rcsb.org\/structure\/5ix0,PDB ID: 5IX0. (Accessed 06 February 2021)."},{"key":"10.1016\/j.phrs.2021.105695_bib60","unstructured":"https:\/\/www.rcsb.org\/structure\/6G3O, PDB ID: 6G3O. (Accessed 06 February 2021)."},{"key":"10.1016\/j.phrs.2021.105695_bib61","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/ng1773","article-title":"A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition","volume":"38","author":"Ropero","year":"2006","journal-title":"Nat. Genet."},{"key":"10.1016\/j.phrs.2021.105695_bib62","doi-asserted-by":"crossref","first-page":"9047","DOI":"10.1158\/0008-5472.CAN-07-0312","article-title":"Reduced body size and decreased intestinal tumor rates in HDAC2-mutant mice","volume":"67","author":"Zimmermann","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2021.105695_bib63","doi-asserted-by":"crossref","first-page":"9331","DOI":"10.1158\/0008-5472.CAN-08-2893","article-title":"Repression of 15-hydroxyprostaglandin dehydrogenase involves histone deacetylase 2 and snail in colorectal cancer","volume":"68","author":"Backlund","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2021.105695_bib64","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1053\/j.gastro.2008.07.078","article-title":"An inactivating mutation in HDAC2 leads to dysregulation of apoptosis mediated by APAF1","volume":"135","author":"Hanigan","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2021.105695_bib65","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.yexcr.2008.01.010","article-title":"HDAC2 deficiency sensitizes colon cancer cells to TNF\u03b1-induced apoptosis through inhibition of NF-\u03baB activity","volume":"314","author":"Kaler","year":"2008","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.phrs.2021.105695_bib66","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1007\/s10620-008-0601-7","article-title":"Global histone H4 acetylation and HDAC2 expression in colon adenoma and carcinoma","volume":"54","author":"Ashktorab","year":"2009","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.phrs.2021.105695_bib67","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/onc.2009.324","article-title":"HDAC inhibitors regulate claudin-1 expression in colon cancer cells through modulation of mRNA stability","volume":"29","author":"Krishnan","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.phrs.2021.105695_bib68","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1007\/s00018-011-0628-3","article-title":"HDAC2 and TXNL1 distinguish aneuploid from diploid colorectal cancers","volume":"68","author":"Gemoll","year":"2011","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.phrs.2021.105695_bib69","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.3390\/cancers6031769","article-title":"Drug resistance in cancer: an overview","volume":"6","author":"Byler","year":"2014","journal-title":"Cancers"},{"key":"10.1016\/j.phrs.2021.105695_bib70","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00280-016-2979-9","article-title":"Histone deacetylase 2 regulates doxorubicin (Dox) sensitivity of colorectal cancer cells by targeting ABCB1 transcription","volume":"77","author":"Ye","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.phrs.2021.105695_bib71","doi-asserted-by":"crossref","first-page":"6103","DOI":"10.1590\/1414-431x20176103","article-title":"MicroRNA-455 suppresses the oncogenic function of HDAC2 in human colorectal cancer","volume":"50","author":"Mao","year":"2017","journal-title":"Braz. J. Med. Biol. Res. Rev. Bras. Pesqui. Med. Biol."},{"key":"10.1016\/j.phrs.2021.105695_bib72","first-page":"1","article-title":"The p300\/YY1\/miR-500a-5p\/HDAC2 signalling axis regulates cell proliferation in human colorectal cancer","volume":"10","author":"Tang","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2021.105695_bib73","first-page":"1404","article-title":"FKBP3 mediates oxaliplatin resistance in colorectal cancer cells by regulating HDAC2 expression","volume":"42","author":"Tong","year":"2019","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.phrs.2021.105695_bib74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-020-01783-9","article-title":"HDAC2 inhibits EMT-mediated cancer metastasis by downregulating the long noncoding RNA H19 in colorectal cancer","volume":"39","author":"Hu","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2021.105695_bib75","doi-asserted-by":"crossref","first-page":"28103","DOI":"10.1371\/journal.pone.0028103","article-title":"Aberrant regulation of HDAC2 mediates proliferation of hepatocellular carcinoma cells by deregulating expression of G1\/S cell cycle proteins","volume":"6","author":"Noh","year":"2011","journal-title":"PloS One"},{"key":"10.1016\/j.phrs.2021.105695_bib76","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.canlet.2013.03.003","article-title":"MiR-145 functions as a tumor suppressor by directly targeting histone deacetylase 2 in liver cancer","volume":"335","author":"Noh","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.phrs.2021.105695_bib77","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1158\/0008-5472.CAN-13-2109","article-title":"HDAC2 provides a critical support to malignant progression of hepatocellular carcinoma through feedback control of mTORC1 and AKT","volume":"74","author":"Noh","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2021.105695_bib78","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/febs.12652","article-title":"Oncogenic potential of CK 2\u03b1 and its regulatory role in EGF\u2010induced HDAC 2 expression in human liver cancer","volume":"281","author":"Kim","year":"2014","journal-title":"FEBS J."},{"key":"10.1016\/j.phrs.2021.105695_bib79","doi-asserted-by":"crossref","first-page":"4752","DOI":"10.1158\/0008-5472.CAN-13-3531","article-title":"Antitumor effects in hepatocarcinoma of isoform-selective inhibition of HDAC2","volume":"74","author":"Lee","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2021.105695_bib80","doi-asserted-by":"crossref","first-page":"95520","DOI":"10.1371\/journal.pone.0095520","article-title":"Melittin restores PTEN expression by down-regulating HDAC2 in human hepatocelluar carcinoma HepG2 cells","volume":"9","author":"Zhang","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.phrs.2021.105695_bib81","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.3892\/mmr.2015.4676","article-title":"1, 25 (OH) 2D3 inhibits the progression of hepatocellular carcinoma via downregulating HDAC2 and upregulating P21 (WAFI\/CIP1)","volume":"13","author":"Huang","year":"2016","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.phrs.2021.105695_bib82","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1600-0463.2005.apm_04.x","article-title":"Increased expression of histone deacetylase 2 is found in human gastric cancer","volume":"113","author":"Song","year":"2005","journal-title":"Apmis"},{"key":"10.1016\/j.phrs.2021.105695_bib83","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S1470-2045(08)70004-4","article-title":"Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis","volume":"9","author":"Weichert","year":"2008","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.phrs.2021.105695_bib84","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1158\/1541-7786.MCR-12-0332","article-title":"Targeted inactivation of HDAC2 restores p16INK4a activity and exerts antitumor effects on human gastric cancer","volume":"11","author":"Kim","year":"2013","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.phrs.2021.105695_bib85","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.gene.2018.09.040","article-title":"Weighted gene co-expression network analysis and connectivity map identifies lovastatin as a treatment option of gastric cancer by inhibiting HDAC2","volume":"681","author":"Zhang","year":"2019","journal-title":"Gene"},{"key":"10.1016\/j.phrs.2021.105695_bib86","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1158\/1535-7163.MCT-05-0480","article-title":"Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells","volume":"5","author":"Hrzenjak","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.phrs.2021.105695_bib87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-018-0978-x","article-title":"HDAC2 depletion promotes osteosarcoma\u2019s stemness both in vitro and in vivo: a study on a putative new target for CSCs directed therapy","volume":"37","author":"La Noce","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2021.105695_bib88","doi-asserted-by":"crossref","first-page":"11583","DOI":"10.1200\/JCO.2018.36.15_suppl.11583","article-title":"Identification of histone deacetylase 2 (HDAC2) as a novel target for MDM2 directed therapies in dedifferentiated liposarcoma","volume":"36","author":"Stets","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2021.105695_bib89","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/2211-5463.12585","article-title":"OzakiT. Histone deacetylase 2 is involved in DNA damage\u2010mediated cell death of human osteosarcoma cells through stimulation of the ATM\/p53 pathway","volume":"9","author":"Sun","year":"2019","journal-title":"FEBS Open Bio"},{"key":"10.1016\/j.phrs.2021.105695_bib90","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.isci.2019.02.008","article-title":"HDAC2 regulates site-specific acetylation of MDM2 and its ubiquitination signaling in tumor suppression","volume":"13","author":"Patel","year":"2019","journal-title":"iScience"},{"key":"10.1016\/j.phrs.2021.105695_bib91","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s10565-019-09459-7","article-title":"HDAC2-mediated upregulation of IL-6 triggers the migration of osteosarcoma cells","volume":"35","author":"Li","year":"2019","journal-title":"Cell Biol. Toxicol."},{"key":"10.1016\/j.phrs.2021.105695_bib92","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1158\/0008-5472.CAN-07-2822","article-title":"Selective inhibition of histone deacetylase 2 silences progesterone receptor\u2013mediated signaling","volume":"68","author":"Bi\u00e7aku","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2021.105695_bib93","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1158\/1535-7163.MCT-08-0985","article-title":"HDAC2 regulates chromatin plasticity and enhances DNA vulnerability","volume":"8","author":"Marchion","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.phrs.2021.105695_bib94","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1038\/onc.2013.332","article-title":"Significance of PELP1\/HDAC2\/miR-200 regulatory network in EMT and metastasis of breast cancer","volume":"33","author":"Roy","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.phrs.2021.105695_bib95","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1093\/jjco\/hyw096","article-title":"HDAC2 overexpression is a poor prognostic factor of breast cancer patients with increased multidrug resistance-associated protein expression who received anthracyclines therapy","volume":"46","author":"Zhao","year":"2016","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2021.105695_bib96","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12935-017-0442-6","article-title":"The role of REST and HDAC2 in epigenetic dysregulation of Nav1. 5 and nNav1. 5 expression in breast cancer","volume":"17","author":"Kamarulzaman","year":"2017","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.phrs.2021.105695_bib97","first-page":"1213","article-title":"HDAC2 overexpression correlates with aggressive clinicopathological features and DNA-damage response pathway of breast cancer","volume":"7","author":"Shan","year":"2017","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.phrs.2021.105695_bib98","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1200\/JCO.2006.08.6165","article-title":"Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study","volume":"25","author":"Munster","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2021.105695_bib99","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/sj.bjc.6605293","article-title":"Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker","volume":"101","author":"Munster","year":"2009","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.phrs.2021.105695_bib100","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1038\/bjc.2011.156","article-title":"A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer","volume":"104","author":"Munster","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.phrs.2021.105695_bib101","first-page":"40","article-title":"Long non-coding RNA ARAP1-AS1 accelerates cell proliferation and migration in breast cancer through miR-2110\/HDAC2\/PLIN1 axis","author":"Lu","year":"2020","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.phrs.2021.105695_bib102","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.7150\/thno.41008","article-title":"SRGN crosstalks with YAP to maintain chemoresistance and stemness in breast cancer cells by modulating HDAC2 expression","volume":"10","author":"Zhang","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.phrs.2021.105695_bib103","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.oraloncology.2008.08.011","article-title":"Histone deacetylase 2 expression predicts poorer prognosis in oral cancer patients","volume":"45","author":"Chang","year":"2009","journal-title":"Oral. Oncol."},{"key":"10.1016\/j.phrs.2021.105695_bib104","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/j.1600-0714.2011.01009.x","article-title":"HDAC2 promotes cell migration\/invasion abilities through HIF\u20101\u03b1 stabilization in human oral squamous cell carcinoma","volume":"40","author":"Chang","year":"2011","journal-title":"J. Oral. Pathol. Med."},{"key":"10.1016\/j.phrs.2021.105695_bib105","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1002\/pmic.201400568","article-title":"Quantitative phosphoproteomic analysis reveals \u03b3\u2010bisabolene inducing p53\u2010mediated apoptosis of human oral squamous cell carcinoma via HDAC2 inhibition and ERK1\/2 activation","volume":"15","author":"Jou","year":"2015","journal-title":"Proteomics"},{"key":"10.1016\/j.phrs.2021.105695_bib106","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1136\/gut.2009.180711","article-title":"HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA","volume":"58","author":"Fritsche","year":"2009","journal-title":"Gut"},{"key":"10.1016\/j.phrs.2021.105695_bib107","doi-asserted-by":"crossref","first-page":"5957","DOI":"10.1038\/onc.2010.332","article-title":"Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects","volume":"29","author":"Marshall","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.phrs.2021.105695_bib108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-4598-9-80","article-title":"HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells","volume":"9","author":"Sch\u00fcler","year":"2010","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.phrs.2021.105695_bib109","doi-asserted-by":"crossref","first-page":"334","DOI":"10.15252\/embr.201541922","article-title":"HDAC2 promotes loss of primary cilia in pancreatic ductal adenocarcinoma","volume":"18","author":"Kobayashi","year":"2017","journal-title":"EMBO Rep."},{"key":"10.1016\/j.phrs.2021.105695_bib110","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1093\/carcin\/bgz067","article-title":"ARHGAP4 regulates the cell migration and invasion of pancreatic cancer by the HDAC2\/\u03b2-catenin signaling pathway","volume":"40","author":"Shen","year":"2019","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.phrs.2021.105695_bib111","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.neuroscience.2018.02.026","article-title":"Suppression of HDAC2 in spinal cord alleviates mechanical hyperalgesia and restores KCC2 expression in a rat model of bone cancer pain","volume":"377","author":"Hou","year":"2018","journal-title":"Neuroscience"},{"key":"10.1016\/j.phrs.2021.105695_bib112","first-page":"1770","article-title":"Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers","volume":"31","author":"Niegisch","year":"2013","journal-title":"InUrologic Oncol. Semin. Orig. Investig."},{"key":"10.1016\/j.phrs.2021.105695_bib113","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.7314\/APJCP.2015.16.8.3543","article-title":"Differentially expressed genes in metastatic advanced Egyptian bladder cancer","volume":"16","author":"Zekri","year":"2015","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.phrs.2021.105695_bib114","doi-asserted-by":"crossref","first-page":"8293","DOI":"10.1007\/s13277-015-4618-1","article-title":"p21 and CK2 interaction-mediated HDAC2 phosphorylation modulates KLF4 acetylation to regulate bladder cancer cell proliferation","volume":"37","author":"Jia","year":"2016","journal-title":"Tumor Biol."},{"key":"10.1016\/j.phrs.2021.105695_bib115","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/sj.bjc.6604199","article-title":"Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy","volume":"98","author":"Weichert","year":"2008","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.phrs.2021.105695_bib116","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/onc.2016.319","article-title":"Beta-adrenergic signaling promotes tumor angiogenesis and prostate cancer progression through HDAC2-mediated suppression of thrombospondin-1","volume":"36","author":"Hulsurkar","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.phrs.2021.105695_bib117","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a018713","article-title":"Erasers of histone acetylation: the histone deacetylase enzymes","volume":"6","author":"Seto","year":"2014","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.phrs.2021.105695_bib118","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nbt.1759","article-title":"Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes","volume":"29","author":"Bantscheff","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.phrs.2021.105695_bib119","doi-asserted-by":"crossref","first-page":"8828","DOI":"10.3390\/ijms21228828","article-title":"Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs)","volume":"21","author":"Luo","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2021.105695_bib120","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.tips.2016.12.006","article-title":"Targeting class,I histone deacetylases in a \u201ccomplex\u201d environment","volume":"38","author":"Millard","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.phrs.2021.105695_bib121","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/imr.12244","article-title":"Targeting protein\u2013protein interactions in hematologic malignancies: still a challenge or a great opportunity for future therapies?","volume":"263","author":"Cierpicki","year":"2015","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.phrs.2021.105695_bib122","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.chembiol.2016.06.011","article-title":"Innovative strategies for selective inhibition of histone deacetylases","volume":"23","author":"Maolanon","year":"2016","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.phrs.2021.105695_bib123","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-41842-6","article-title":"HDAC1 and HDAC2 independently regulate common and specific intrinsic responses in murine enteroids","volume":"9","author":"Gonneaud","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2021.105695_bib124","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1039\/C4SC02130D","article-title":"Kinetically selective inhibitors of histone deacetylase 2 (HDAC2) as cognition enhancers","volume":"6","author":"Wagner","year":"2015","journal-title":"Chem. Sci."},{"key":"10.1016\/j.phrs.2021.105695_bib125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms11262","article-title":"Insights into the activation mechanism of class I HDAC complexes by inositol phosphates","volume":"7","author":"Watson","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2021.105695_bib126","doi-asserted-by":"crossref","first-page":"3795","DOI":"10.1016\/j.bmc.2013.04.036","article-title":"Structural basis for the design and synthesis of selective HDAC inhibitors","volume":"21","author":"Di Micco","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.phrs.2021.105695_bib127","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113332","article-title":"Histone deacetylase 2: A potential therapeutic target for cancer and neurodegenerative disorders","volume":"216","author":"Gediya","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.phrs.2021.105695_bib128","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1039\/b703830p","article-title":"Isoform-selective histone deacetylase inhibitors","volume":"37","author":"Bieliauskas","year":"2008","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.phrs.2021.105695_bib129","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3389\/fnmol.2017.00357","article-title":"Combinatorial in silico strategy towards identifying potential hotspots during inhibition of structurally identical HDAC1 and HDAC2 enzymes for effective chemotherapy against neurological disorders","volume":"10","author":"Ganai","year":"2017","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.phrs.2021.105695_bib130","first-page":"1","article-title":"Exploring structural requirements of isoform selective histone deacetylase inhibitors: a comparative in silico study","volume":"38","author":"Kashyap","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.phrs.2021.105695_bib131","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.apsb.2011.10.002","article-title":"Design, synthesis and biological evaluation of novel histone deacetylase inhibitors based on virtual screening","volume":"1","author":"Lu","year":"2011","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.phrs.2021.105695_bib132","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s00044-010-9519-7","article-title":"Discovery of a novel histone deacetylase 8 inhibitor by virtual screening","volume":"21","author":"Zhang","year":"2012","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.phrs.2021.105695_bib133","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.canlet.2008.08.016","article-title":"HDAC family: What are the cancer relevant targets?","volume":"277","author":"Witt","year":"2009","journal-title":"Cancer Lett."},{"key":"10.1016\/j.phrs.2021.105695_bib134","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3389\/fnmol.2017.00357","article-title":"Combinatorial in silico strategy towards identifying potential hotspots during inhibition of structurally identical HDAC1 and HDAC2 enzymes for effective chemotherapy against neurological disorders","volume":"10","author":"Ganai","year":"2017","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.phrs.2021.105695_bib135","article-title":"Regulating the regulators: the post-translational code of class I HDAC1 and HDAC2","volume":"2011","author":"Segr\u00e9","year":"2011","journal-title":"J. Biomed. Biotechnol."},{"key":"10.1016\/j.phrs.2021.105695_bib136","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1021\/np400198r","article-title":"a potent and selective histone deacetylase inhibitor from the Panamanian marine cyanobacterium cf","volume":"76","author":"Pavlik","year":"2013","journal-title":"Symploca Sp. J. Nat. Prod."},{"key":"10.1016\/j.phrs.2021.105695_bib137","doi-asserted-by":"crossref","first-page":"12447","DOI":"10.1111\/cpr.12447","article-title":"Pharmacological or transcriptional inhibition of both HDAC 1 and 2 leads to cell cycle blockage and apoptosis via p21Waf1\/Cip1 and p19INK4d upregulation in hepatocellular carcinoma","volume":"51","author":"Zhou","year":"2018","journal-title":"Cell Prolif."},{"key":"10.1016\/j.phrs.2021.105695_bib138","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.3390\/nu10111784","article-title":"Rosmarinic Acid, a component of rosemary tea, induced the cell cycle arrest and apoptosis through modulation of HDAC2 expression in prostate cancer cell lines","volume":"10","author":"Jang","year":"2018","journal-title":"Nutrients"},{"key":"10.1016\/j.phrs.2021.105695_bib139","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.gene.2017.09.034","article-title":"Design, virtual screening, molecular docking and molecular dynamics studies of novel urushiol derivatives as potential HDAC2 selective inhibitors","volume":"637","author":"Zhou","year":"2017","journal-title":"Gene"},{"key":"10.1016\/j.phrs.2021.105695_bib140","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1021\/ml400158k","article-title":"Tropolones as lead-like natural products: the development of potent and selective histone deacetylase inhibitors","volume":"4","author":"Ononye","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.phrs.2021.105695_bib141","first-page":"1","article-title":"Novel hydroxamic acids incorporating 1-((1H-1, 2, 3-Triazol-4-yl) methyl)-3-hydroxyimino-indolin-2-ones: synthesis, biological evaluation, and SAR analysis","volume":"130","author":"Anh","year":"2018","journal-title":"J. Chem. Sci."},{"key":"10.1016\/j.phrs.2021.105695_bib142","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1021\/cb500767c","article-title":"Computational design of a time-dependent histone deacetylase 2 selective inhibitor","volume":"10","author":"Zhou","year":"2015","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.phrs.2021.105695_bib143","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.bmcl.2007.12.031","article-title":"Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1\/HDAC2 inhibitors (SHI-1: 2)","volume":"18","author":"Methot","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.phrs.2021.105695_bib144","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.chembiol.2013.03.020","article-title":"Selective HDAC1\/HDAC2 inhibitors induce neuroblastoma differentiation","volume":"20","author":"Frumm","year":"2013","journal-title":"Chem. Biol."},{"key":"10.1016\/j.phrs.2021.105695_bib145","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1158\/1078-0432.CCR-14-1290","article-title":"Selective inhibition of HDAC1 and HDAC2 as a potential therapeutic option for B-ALL","volume":"21","author":"Stubbs","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2021.105695_bib146","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2174\/1386207318666150706103918","article-title":"Discovery of a novel HDAC2 inhibitor by a scaffold-merging hybrid query","volume":"18","author":"Basant","year":"2015","journal-title":"Comb. Chem. High. Throughput Screen."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661821002796?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661821002796?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:24:54Z","timestamp":1760912694000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661821002796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":146,"alternative-id":["S1043661821002796"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2021.105695","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Histone deacetylase 2 selective inhibitors: A versatile therapeutic strategy as next generation drug target in cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2021.105695","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105695"}}